Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalSamra Turajlic, Nicos Fotiadis, Hang Xu et al.|Cell|2018Cited by 680
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanomaPaolo A. Ascierto, Antoni Ribas, Pier Francesco Ferrucci et al.|Nature Medicine|2019Cited by 328
Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for <i>BRAF</i>-mutant advanced melanoma: Phase 1 KEYNOTE-022 study.Antoni Ribas, Omid Hamid, Wilson H. Miller et al.|Journal of Clinical Oncology|2016Cited by 49
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).Georgina V. Long, Antoni Ribas, Omid Hamid et al.|Journal of Clinical Oncology|2016Cited by 12